Cytokinetics, Incorporated (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics, stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total transaction of $55,124.40. Following the completion of the transaction, the insider now directly owns 17,982 shares in the company, valued at $232,687.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Caryn Gordon Mcdowell also recently made the following trade(s):

  • On Friday, October 6th, Caryn Gordon Mcdowell sold 13,181 shares of Cytokinetics, stock. The stock was sold at an average price of $15.49, for a total transaction of $204,173.69.
  • On Wednesday, September 6th, Caryn Gordon Mcdowell sold 10,131 shares of Cytokinetics, stock. The stock was sold at an average price of $14.60, for a total transaction of $147,912.60.
  • On Tuesday, August 8th, Caryn Gordon Mcdowell sold 11,348 shares of Cytokinetics, stock. The stock was sold at an average price of $12.47, for a total transaction of $141,509.56.

Cytokinetics, Incorporated (NASDAQ:CYTK) traded down $0.80 on Monday, reaching $12.80. 377,296 shares of the company’s stock traded hands, compared to its average volume of 452,107. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.21 and a current ratio of 7.60.

Cytokinetics, (NASDAQ:CYTK) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. Cytokinetics, had a negative net margin of 172.27% and a negative return on equity of 62.64%. The business had revenue of $6.18 million for the quarter, compared to analysts’ expectations of $5.35 million. equities research analysts forecast that Cytokinetics, Incorporated will post -2.39 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/06/cytokinetics-incorporated-cytk-insider-caryn-gordon-mcdowell-sells-4260-shares.html.

Several research analysts recently commented on the stock. BidaskClub raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Zacks Investment Research downgraded shares of Cytokinetics, from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Cytokinetics, in a research report on Monday, September 18th. TheStreet downgraded shares of Cytokinetics, from a “c” rating to a “d” rating in a research report on Friday, October 27th. Finally, HC Wainwright reissued a “buy” rating and set a $26.00 price objective on shares of Cytokinetics, in a research report on Wednesday, September 20th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $21.60.

A number of institutional investors have recently added to or reduced their stakes in the stock. Comerica Bank increased its holdings in Cytokinetics, by 10.8% in the 3rd quarter. Comerica Bank now owns 53,054 shares of the biopharmaceutical company’s stock worth $737,000 after acquiring an additional 5,192 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Cytokinetics, by 4.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 552,300 shares of the biopharmaceutical company’s stock worth $8,008,000 after acquiring an additional 25,510 shares in the last quarter. Rhumbline Advisers increased its holdings in Cytokinetics, by 6.6% in the 3rd quarter. Rhumbline Advisers now owns 88,056 shares of the biopharmaceutical company’s stock worth $1,277,000 after acquiring an additional 5,470 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Cytokinetics, in the 3rd quarter worth approximately $799,000. Finally, Municipal Employees Retirement System of Michigan increased its holdings in Cytokinetics, by 74.7% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 18,990 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 8,120 shares in the last quarter. 71.02% of the stock is owned by institutional investors.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.